Suara.com – So far, the Pfizer vaccine proven to be 95 percent effective in preventing transmission corona virus Covid-19 deliver impressive results for England. The UK is the first country to use the Pfizer vaccine to vaccinate its citizens.
Previously, the manufacturing process the Covid-19 vaccine This was a cause for concern because it showed side effects.
However, the latest data reveal that the vaccine is quite effective in preventing the transmission of the Covid-19 corona virus with just one dose injection.
The Food and Drug Administration (FDA) has granted emergency authorization for vaccines manufactured by Pfizer-BioNTech.
Also Read:
Corona Covid-19 Virus Side Effects, This Man Experienced Blindness and Amputation
This Pfizer vaccine has shown impressive results during large-scale trials with tens of thousands of participants, which demonstrated an efficacy of 95 percent in preventing the Covid-19 corona virus.
In addition, the vaccine should be given in two doses, prime and booster, with an interval of 21 to 28 days.
But reported from Express, the latest data reveal that the Pfizer vaccine is actually enough to be given once with a single dose to prevent transmission of the Covid-19 corona virus.
Health experts say the Pfizer vaccine data in a single dose can be divided more. Vaccinations could be given to more people than originally planned to reduce the number of cases.
In the UK, government policy has mandated an approach with the launch of the Pfizer vaccine starting with the elderly and the most vulnerable people to prevent transmission of the Covid-19 corona virus.
Also Read:
French Study: Corona Covid-19 Virus is 3 Times More Deadly than Flu
Currently, health workers focus on the first of the nine phases of vaccination, especially when they vaccinate nursing home residents over 80 years of age and their caregivers.
The remaining eight will cover ages 50 to 75, but will also include vulnerable children and younger adults.
The makers of the three vaccines that appear closest to broad distribution include AstraZeneca, Pfizer and Moderna estimate a total production capacity of 5.3 billion doses for 2021, which could cover between 2.6 billion and 3.1 billion people worldwide.
In Europe, 27 European Union member states along with five other rich countries have pre-ordered the vaccine. These countries only cover about 13 percent of the global population.
– .
